HM-002-1005 - A Phase 1, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 08 Apr 2025
At a glance
- Drugs HM 002 1005 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Hua Medicine
Most Recent Events
- 31 Mar 2025 Status changed from recruiting to completed.
- 19 Jul 2024 New trial record